POMBILITI ATGA (cipaglucosidase alfa-atga)

Office-Administration – intravenous (IV) infusion

Diagnosis considered for coverage:
  • Indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT)
Coverage Criteria:

For diagnosis of Late-Onset Pompe disease:

  • Diagnosis of late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency); AND
  • Disease is confirmed by one of the following:
    • Absence or deficiency (less than 40% of the lab specific normal mean) of GAA enzyme activity in lymphocytes, fibroblasts, or muscle tissues as confirmed by an enzymatic assay 
    • Molecular genetic testing confirms mutations in the GAA gene; AND
  • Presence of clinical signs and symptoms of the disease (e.g., respiratory distress, skeletal muscle weakness, etc.); AND
  • Medication is used in combination with Opfolda (miglustat); AND
  • Patient weight is greater than or equal to 40 kg; AND
  • Trial and inadequate response to one of the following:
    • Lumizyme 
    • Nexviazyme; AND
  • Not to be used in combination with other miglustat products (i.e., Zavesca, Yargesa)
Reauthorization Criteria:

For diagnosis of Late-Onset Pompe disease:

  • Patient demonstrates positive clinical response to therapy (e.g., improvement in FVC, improvement in 6-minute walk distance [6MWD]); AND
  • Medication is used in combination with Opfolda (miglustat); AND
  • Not to be used in combination with other miglustat products (i.e., Zavesca, Yargesa)
Dosing:

Late-Onset Pompe disease:

  • 20 mg/kg (of actual body weight) administered every other week as an intravenous infusion
  • Pombiliti must be administered in combination with Opfolda. If the Opfolda dose is missed, Pombiliti should not be administered
Coverage Duration:
  • Initial: 1 year
  • Reauthorization: 2 years
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • Consensus recommendation based on current clinical guidelines indicate that treatment should be started in patients with late onset Pompe disease when they become symptomatic and/or show signs of disease progression
  • Prior to Pombiliti administration, consider pretreating with antihistamines, antipyretics, and/or corticosteroids. If premedication was used with previous enzyme replacement therapy (ERT), prior to Pombiliti administration, pretreat with antihistamines, antipyretics, and/or corticosteroids
Policy Updates:
  • Effective 6/01/2024 – New policy approved by WHA P&T Committee. (P&T, 05/21/2024)
References:
  • Pombiliti Prescribing Information. Amicus Therapeutics US, LLC. Philadelphia, PA. Sept 2023. 
  • Diaz, C., Diaz-Manera, J. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759116/. Accessed November 2, 2023. 
  • Cleveland Clinic - Pompe Disease. Available at: https://my.clevelandclinic.org/health/diseases/15808-pompe-disease. Accessed November 2, 2023. 
  • Cupler, E., Berger, K., Leshner, R., et al. Consensus Treatment Recommendations for Late-Onset Pompe Disease. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534745/. Accessed November 2, 2023. 
  • Barba-Romero MA, Barrot E, Bautista-Lorite J, et al. Clinical guidelines for late-onset Pompe disease. Available at: https://www.orpha.net/data/patho/Cpg/en/PompeLateOnset_ES_en_CPG_ORPHA420429.pdf. Accessed November 2, 2023.

Last review date: June 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone